Answers are grounded in this paper and cite their sources.
.) after allo-HSCT with RIC. The use of RIC regimens offers an opportunity of achieving full-donor engraftment with GvT effect, as well as, a reduced transplant-related mortality. Current literature suggests that allo-HSCT with RIC might become a choice for elderly and medically fragile patients with refractory metastatic solid tumors.
No takes yet. Share an insight, caveat, or question.
Karadurmuş et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: